PubMed Health⌕ Search

PubMed · 2728029

Molecular differences between type A botulinum neurotoxin and its toxoid.

Abstract

The neurotoxins (seven serotypes, Mr approximately 150,000) produced by Clostridium botulinum cause the neuroparalytic disease botulism. Prophylaxis, definitive diagnosis and the only effective therapy for botulism depend, at present, on chemically detoxified form(s) of the neurotoxins, i.e. toxoids (immunogens), and the antisera raised with the immunogens. And yet, the toxoids currently used for immunization of humans and animals and for raising antibody are very crude preparations (approximately 90% impure) of the neurotoxins. Hence, the highly heterogenous toxoids were not suitable for physicochemical studies. We have detoxified a pure (greater than 99%) neurotoxin (serotype A) with formaldehyde. The native neurotoxin is composed of two subunit chains (Mr 53,000 and 97,000). The physicochemical properties of the toxoid (immunogenic in rabbits) were analyzed. The chemical modification produced inter- and intrasubunit covalent links at multiple sites and thus extensive aggregation of the neurotoxin. The secondary structure parameters (alpha-helix, beta-sheet, beta-turn and random coil) of the native protein were not significantly altered. Tertiary structure, as measured by exposure of tyrosine residues and fluorescence quantum yield of tryptophan residues, was considerably altered. The data imply that conformational (topographical) antigenic determinants may not contribute significantly to the serological property of the neurotoxin.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B R Singh, B R DasGupta. 1989. Molecular differences between type A botulinum neurotoxin and its toxoid.. https://doi.org/10.1016/0041-0101(89)90202-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Botulinum Toxins↗

Human milk SIgA binds to botulinum type B 16S toxin and limits toxin adherence on T84 cells.

Botulinum neurotoxin produced by Clostridium botulinum type B is in the form of a complex of 12S and 16S toxins. Food-borne botulism is caused by these complex toxins which are ingested orally and absorbed from the digestive tract. Here, we show that the human milk SIgA binds to the type B16S toxin. The binding of SIgA to 16S toxin and HA was inhibited by carbohydrates such as galactose, suggesting that the interaction of carbohydrate side chain of the SIgA with the HA of the 16S toxin is important for SIgA-16S complex formation. We also demonstrate that SIgA inhibits the attachment of 16S toxin to intestinal epithelial cells. These data suggest that the interaction of antigen nonspecific SIgA with 16S toxin has a large influence on the absorption of 16S toxin from the intestinal epithelium, and that SIgA may provide insight into developing a therapeutic agent for type B food-borne botulism.

Botulinum Toxins↗